LONDON (Alliance News) - Destiny Pharma PLC on Monday reported positive results in a second phase 1 clinical study examining the anti-irritation features of its XF-73 nasal gel.
The study, which was commenced in February 2018, achieved its primary objective of a low cumulative irritancy score for both concentration levels, with high statistical significance when compared to a placebo of distilled water, Destiny Pharma explained.
Chief Executive Officer Neil Clark said: "We are very pleased with the positive outcome in this second phase 1 study, which confirms the good safety profile of the XF-73 nasal gel formulation. We will now finalise plans for our key phase 2b study testing XF-73 nasal gel as a novel therapy for the prevention of post-surgical staphylococcal infections."
The phase 1 study enrolled 35 volunteers who received the gel daily for 21 consecutive days on both intact and abraded skin.
Destiny Pharma shares were trading up 3.9% at 76.90 pence each.
Destiny Pharma. (DEST)